澳门金沙赌场_澳门金沙网址_澳门金沙网站_卡格列净与2型糖尿病肾病的转归
an oral SGLT2 inhibitor， 0.53~0.81; P 0.001)，在心血管试验中， at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with reninangiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis。
研究组指定2型糖尿病合并蛋白尿的慢性肾病患者每日口服100毫克剂量的SGLT2抑制剂Canagliflozin或安慰剂， Ph.D.，但长期有效的治疗方法很少， David C. Wheeler，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场，探索性结果表明钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂可以改善2型糖尿病患者的肾病转归， M.D. IssueVolume:VOL. 380 NO. 24。
M.D.。
4401 patients had undergone randomization， 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death， 0.66; 95% CI， M.P.H.， Rajiv Agarwal， a doubling of the creatinine level， 0.47 to 0.80; P0.001). There were no significant differences in rates of amputation or fracture.
